# ARTEMIS-001 (NCT05276609)

> ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

- Drugs tested: risvutatug rezetecan (HS-20093)
- Indication: locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05276609
- Phase: PHASE1
- Status: UNKNOWN
- Sponsor: Shanghai Hansoh Biomedical Co., Ltd
- Conditions: Advanced Solid Tumor
- Interventions: HS-20093 (Phase Ia: Dose escalation); HS-20093 (Phase Ib: Dose expansion)
- Enrollment: 177
- Primary outcome: Ⅰa (Dose-Escalation Stage): Maximum tolerated dose (MTD) for HS-20093
- Primary outcome: Ⅰb (Dose-Expansion Stage): Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

## Indexed commentary on ARTEMIS-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 10 posts on X
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=artemis-001-nct05276609

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05276609", "email": "<work email>"}; the inbox owner confirms by the emailed link.